CRISPR-Cas9 editing of human pluripotent stem cells

• Use authenticated hESC or hiPSC cultures maintained under pluripotent stem-cell culture conditions, dissociation reagent suitable for hPSC passaging, ROCK inhibitor during stressful single-cell handling, CRISPR-Cas9 plasmid or Cas9 ribonucleoprotein, sgRNA or crRNA:tracrRNA, PCR primers for target genotyping, and optional ssODN, plasmid, or AAV donor templates for homology-directed repair^{[1][2][3][6][7]}.

• Use pluripotency validation reagents such as OCT4, SOX2, NANOG, TRA-1-60, or TRA-1-81 detection reagents when clone characterization is required, and use DNA analysis reagents for PCR, Sanger sequencing, amplicon sequencing, or fragment analysis to confirm the intended edit and exclude major unwanted on-target events^[1][2][4][6].

• Use a sterile tissue-culture system for hPSC maintenance, an electroporation or nucleofection platform for CRISPR delivery, fluorescence-activated cell sorting when fluorescent enrichment or reporter isolation is used, standard PCR and sequencing equipment for genotyping, and karyotype or genomic integrity testing methods for final clone qualification^{[1][2][3][4][8]}.

• Design one or more guide RNAs near the intended edit site; for knockout, guides can target coding exons or paired sites to delete a defined region, while precise knock-in requires a donor template with homology to the target locus and sequence changes that prevent repeated Cas9 cutting when possible^{[1][3][4][5][6]}.

• Prepare healthy hPSC cultures before editing, because published protocols emphasize editing actively maintained pluripotent cultures and then expanding individual clones only after recovery and selection or enrichment when used^[1][2][6][8].

• Dissociate hPSCs to the format required by the selected published delivery method, deliver Cas9 with guide RNA by nucleofection, electroporation, plasmid transfection, RNP electroporation, or RNP plus viral donor delivery, and include donor DNA only for HDR-based knock-in or correction experiments^{[1][2][3][6][7]}.

• After delivery, allow edited cells to recover under hPSC culture conditions, enrich edited cells when the selected method uses fluorescence or selection, and expand either bulk populations for initial efficiency assessment or single-cell-derived colonies for clonal line generation^{[1][2][3][4][8]}.

• For knockout workflows, screen clones for frameshift indels, biallelic deletions, or donor-free paired-guide deletions; for knock-in workflows, screen for correct junctions, intended sequence incorporation, zygosity, and absence of undesired indels on the targeted allele^{[1][3][4][5][6]}.

• Analyze editing efficiency first in the bulk population when feasible, then genotype individual clones by PCR and sequencing; reporter knock-in studies should distinguish correctly targeted reporter-positive clones from clones carrying indels or other unwanted target-locus mutations^[1][2][4][8].

• Use unedited parental hPSCs as the negative control, a previously validated guide or reporter-editing construct as a positive technical control when available, and independently derived clones as biological units for downstream phenotyping^[1][2][6][8].

• Final clone release should include confirmation of the intended edit, exclusion of major unintended on-target configurations, assessment of pluripotency marker expression, and genomic integrity testing such as karyotyping when the edited line will be used for disease modeling or differentiation studies^{[1][2][3][4][8]}.

Problem: Low editing efficiency.

• Possible Cause: Inefficient guide RNA, delivery method, or donor-template configuration.
• Literature-supported Solution: Test multiple guides near the target, confirm editing in bulk cells before clone picking, and consider RNP-based delivery or AAV donor delivery for HDR workflows when supported by the target design^{[1][2][3][6][7]}.

Problem: Correct knock-in signal is accompanied by indels at the targeted allele.

• Possible Cause: Cas9 can continue cutting the edited allele if the guide-recognition sequence remains intact.
• Literature-supported Solution: Design donor templates that disrupt the guide site or PAM without changing the desired protein sequence when possible, and genotype both junctions and the edited allele sequence^[3][4][6].

Problem: Apparent homozygous knockout may actually reflect larger on-target deletion or allele loss.

• Possible Cause: CRISPR-Cas9 can generate larger on-target rearrangements that simple PCR assays may miss.
• Literature-supported Solution: Use assays that distinguish biallelic edits from hemizygous loss, such as multiple PCR amplicons across the locus, copy-number analysis, or sequencing-based confirmation^[5][9].

Problem: Edited clones fail downstream quality control.

• Possible Cause: hPSC editing and clonal expansion can select abnormal or poorly pluripotent clones.
• Literature-supported Solution: Retain multiple independently edited clones and release only clones with the intended genotype, pluripotency marker expression, and acceptable genomic integrity testing^[1][2][3][8].